Welcome to our dedicated page for Inhibrx Biosciences news (Ticker: INBX), a resource for investors and traders seeking the latest updates and insights on Inhibrx Biosciences stock.
Inhibrx Biosciences Inc (INBX) is a clinical-stage biopharmaceutical innovator developing targeted therapies for oncology and rare diseases through advanced protein engineering. This dedicated news hub provides investors and industry observers with comprehensive access to official corporate communications and verified developments.
Our curated collection features INBX's latest press releases, regulatory filings, and clinical trial updates. Track progress across therapeutic programs including multivalent biologics and optimized antibody candidates designed through the company's proprietary modular platforms. Stay informed about strategic partnerships, research milestones, and financial disclosures that shape INBX's position in biopharmaceutical innovation.
Key updates include clinical development timelines, intellectual property advancements, and collaborative research initiatives. All content is sourced directly from company filings and authorized statements to ensure reliability. Bookmark this page for streamlined access to INBX's evolving pipeline and corporate announcements, presented with neutral analysis suitable for both institutional and individual investors.
Inhibrx, Inc. (Nasdaq: INBX) reported its financial results for Q2 2021, showing cash and cash equivalents of $125.7 million, a slight decrease from $128.7 million at year-end 2020. R&D expenses decreased to $17.9 million, down from $19.0 million in Q2 2020, while G&A expenses rose to $2.9 million from $1.5 million. The company recorded a net loss of $20.7 million ($0.55 per share), compared to a net loss of $17.9 million ($0.99 per share) in the same quarter last year. The financial report reflects ongoing development in its clinical programs.
Inhibrx, Inc. (Nasdaq: INBX) announced the initiation of a potential registration-enabling Phase 2 study of INBRX-109 for chondrosarcoma, an orphan bone cancer with no approved treatments. The drug has shown promising results in an ongoing Phase 1 trial with disease control in 87.5% of patients. An additional loan agreement with Oxford Finance was amended, providing $40M in capital. The FDA granted Fast Track designation to INBRX-109 in January 2021. The new Phase 2 trial aims to evaluate the drug's efficacy through progression-free survival metrics.
Inhibrx, Inc. (NASDAQ: INBX), a clinical-stage biotechnology firm, will present at two upcoming virtual investor conferences: the Jefferies Healthcare Conference on June 2 at 12:30 p.m. PT and the JMP Securities Life Sciences Conference on June 17 at 8:00 a.m. PT. Live webcasts of these presentations can be accessed through the investor section of Inhibrx's website and will remain available for 60 days post-event. The company focuses on developing biologic therapeutic candidates for oncology and orphan diseases, utilizing advanced protein engineering techniques.
Inhibrx, Inc. (Nasdaq: INBX) reported its Q1 2021 financial results on May 13, 2021. The company had cash and cash equivalents of $108 million, a decrease from $128.7 million at the end of 2020. R&D expenses dropped to $16.4 million, while G&A expenses rose to $3 million due to increased personnel costs. The net loss for the quarter was $19.3 million or $0.51 per share, an improvement from $20.1 million or $1.11 per share in Q1 2020. Inhibrx is progressing with its four clinical programs and expects data from all by year-end.
Inhibrx, Inc. (Nasdaq: INBX) announced its fourth quarter and fiscal year 2020 financial results, highlighting a transformative year with advancements in four clinical programs. The Phase 1 study of INBRX-105 showed a maximum tolerated dose of 1 mg/kg, with 44% of evaluable patients achieving stable disease. Cash and cash equivalents grew significantly to $128.7 million at year-end. However, the company reported a net loss of $76.1 million for the fiscal year, worsening from a net loss of $51.4 million in 2019.
Inhibrx, Inc. (Nasdaq: INBX) announced its participation in the Guggenheim Healthcare Talks: 2021 Oncology Days, scheduled for February 12, 2021, at 2 p.m. Pacific Time. The presentation will be webcast live, accessible via the investor section of the Inhibrx website, and available for 60 days post-event. Inhibrx is focused on developing a pipeline of novel biologic therapies for oncology and orphan diseases, utilizing its proprietary sdAb platform and collaborating with companies like bluebird bio and Bristol-Myers Squibb.
Inhibrx, a clinical-stage biotechnology company, announced that the FDA granted Fast Track designation to INBRX-109 for treating patients with unresectable or metastatic conventional chondrosarcoma. This innovative therapeutic candidate is designed to induce tumor-selective programmed cell death through death receptor 5 (DR5). The designation facilitates the development and review process of drugs for serious conditions. A Phase 2 study of INBRX-109 is planned for mid-2021, aiming to demonstrate efficacy in enhancing patient outcomes where no approved therapies currently exist.
Inhibrx, Inc. (Nasdaq: INBX) reported its Q3 2020 financial results, showing a net loss of $20.5 million, or $0.77 per share, slightly worse than the $20.2 million loss in Q3 2019. Cash and cash equivalents increased significantly to $127.7 million from $11.5 million at the end of 2019, bolstered by their recent IPO, which raised $126 million. The company expects multiple clinical data read-outs and new program initiations over the next two years, aided by an amended loan agreement with Oxford Finance LLC that enhances their financial flexibility.
Inhibrx, Inc. (Nasdaq: INBX) announced promising interim results from a Phase 1 clinical trial of INBRX-109, a treatment for chondrosarcoma, an orphan bone cancer. Out of 12 evaluable patients, 92% showed disease control, with 67% experiencing a reduction in tumor burden. Two patients had significant tumor size reductions of 60% and 32%. Favorable safety profiles were noted, with no serious adverse events reported. The company plans future discussions with the FDA for a registration-enabling study in Q2 2021, alongside expanding trials for other cancers.
Inhibrx, a clinical-stage biotechnology company (Nasdaq: INBX), announced its participation in several upcoming investor and scientific conferences. Presentations will occur at the:
- The 29th Annual Credit Suisse Virtual Healthcare Conference on November 12 at 3:30 p.m. ET,
- Jefferies Virtual London Healthcare Conference on November 17 at 2:10 p.m. ET,
- CTOS 2020 Virtual Annual Meeting on November 20 at 9:00 a.m. ET,
- Evercore's Annual Conference on December 3 at 3:30 p.m. ET.
Each event will be available via live webcast on their investor website.
FAQ
What is the current stock price of Inhibrx Biosciences (INBX)?
What is the market cap of Inhibrx Biosciences (INBX)?
